Skip to main content

Table 3 KM curve optimum fitting distribution and parameters

From: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China

 

Optimum fitting distribution

Survival function

Fitting parameters

μ

σ

OS curve(sintilimab-combination group)

lognormal

S(t) = 1-φ〔(logt-μ)/σ〕

3.2277

1.1832

OS curve(placebo-combination group)

lognormal

2.7519

1.1003

PFS curve(sintilimab-combination group)

lognormal

2.2309

1.0708

PFS curve(placebo-combination group)

lognormal

1.6359

0.8141